However, HER2-directed therapies do not have regulatory approval for use in HER2-positive SGC in the UK, Europe, or the US, and there is no guidance on the selection of HER2-directed therapy or its sequencing alongside other anti-cancer therapies. This evidence concerns the gene ERBB2 and cancer.